-
Parental inflammatory bowel disease and autism in children
AbstractEvidence linking parental inflammatory bowel disease (IBD) with autism in children is inconclusive. We conducted four complementary studies to investigate associations between parental IBD and
2023-02-27
-
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access
Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which inhibit PD-1, have greatly improved survival for many patients with cancer, but are prohibitively expensive and unattainable for
2023-02-27
-
In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation
AbstractDespite scientific evidence originating from two patients published to date that CCR5Δ32/Δ32 hematopoietic stem cell transplantation (HSCT) can cure human immunodeficiency virus type 1 (HIV-1)
2023-02-21
-
Dementia research needs a global approach
The international community needs to prioritize research on interventions and preventative measures for dementia that are likely to produce the greatest global impact.Dementia is the seventh leading c
2023-02-18
-
![New and emerging approaches to treat psychiatric disorders]()
New and emerging approaches to treat psychiatric disorders
AbstractPsychiatric disorders are highly prevalent, often devastating diseases that negatively impact the lives of millions of people worldwide. Although their etiological and diagnostic heterogeneity
2023-02-18
-
![CRISPR gene-editing therapies for hypertrophic cardiomyopathy]()
CRISPR gene-editing therapies for hypertrophic cardiomyopathy
Pre-symptomatic gene editing in preclinical models of hypertrophic cardiomyopathy shows therapeutic promise; clinical studies are now needed to assess safety and efficacy in humans.The two groups use
2023-02-18
-
![First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial]()
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
AbstractFirst-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previo
2023-02-03
-
![Seeking therapeutic synergy in BRAF mutant colorectal cancer]()
Seeking therapeutic synergy in BRAF mutant colorectal cancer
In a phase I trial, the combination of dabrafenib, trametinib and spartalizumab uncovers the crosstalk between the MAPK pathway and the immune system, which offers a promising new strategy to improve
2023-01-31